Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387:2641–54.

Article  CAS  PubMed  Google Scholar 

Lachmann HJ, Hawkins PN. Systemic amyloidosis. Curr Opin Pharmacol. 2006;6:214–20.

Article  CAS  PubMed  Google Scholar 

Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med (Lond). 2018;18:s30–5.

Article  PubMed  Google Scholar 

Fontana M, Ćorović A, Scully P, Moon JC. Myocardial amyloidosis: the exemplar interstitial disease. JACC Cardiovasc Imaging. 2019;12:2345–56.

Article  PubMed  Google Scholar 

Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. Cardiovasc Res Cardiovasc Res. 2022. https://doi.org/10.1093/cvr/cvac119.

Article  Google Scholar 

Ravichandran S, Lachmann HJ, Wechalekar AD. Epidemiologic and Survival Trends in Amyloidosis, 1987–2019. N Eng J Med. 2020;382:1567–8.

Article  Google Scholar 

Lauppe RE, Liseth Hansen J, Gerdesköld C, Rozenbaum MH, Strand AM, Vakevainen M, et al. Original research: nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden. Open Heart. 2021;8:1755.

Article  Google Scholar 

Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40:232–9.

Article  CAS  PubMed  Google Scholar 

Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJM, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid. 2016;23:209–13.

Article  CAS  PubMed  Google Scholar 

Patel RK, Ioannou A, Razvi Y, Chacko L, Venneri L, Bandera F, et al. Sex differences among patients with transthyretin amyloid cardiomyopathy—from diagnosis to prognosis. Eur J Heart Fail. 2022. https://doi.org/10.1002/ejhf.2646.

Article  PubMed  Google Scholar 

Ioannou A, Patel R, Gillmore JD, Fontana M. Imaging-guided treatment for cardiac amyloidosis. Curr Cardiol Rep. 2022;1:1–12.

Google Scholar 

Ioannou A, Patel RK, Razvi Y, Porcari A, Knight D, Martinez-Naharro A, et al. Multi-imaging characterization of cardiac phenotype in different types of amyloidosis. JACC Cardiovasc Imaging. 2022. https://doi.org/10.1016/j.jcmg.2022.07.008.

Article  PubMed  Google Scholar 

Carr AS, Pelayo-Negro AL, Evans MRB, Laurà M, Blake J, Stancanelli C, et al. A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK. J Neurol Neurosurg Psychiatry. 2016;87:620–7.

Article  CAS  PubMed  Google Scholar 

Yanagisawa A, Ueda M, Sueyoshi T, Okada T, Fujimoto T, Ogi Y, et al. Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis. Mod Pathol. 2015;28:201–7.

Article  CAS  PubMed  Google Scholar 

Geller HI, Singh A, Alexander KM, Mirto TM, Falk RH. Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis. JAMA. 2017;318:962–3.

Article  PubMed  PubMed Central  Google Scholar 

Coelho T, Maurer MS, Suhr OB. THAOS—The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013;29:63–76.

Article  CAS  PubMed  Google Scholar 

Rowczenio DM, Noor I, Gillmore JD, Lachmann HJ, Whelan C, Hawkins PN, et al. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat. 2014;35:E2403–12.

Article  CAS  PubMed  Google Scholar 

Waddington-Cruz M, Wixner J, Amass L, Kiszko J, Chapman D, Ando Y, et al. Characteristics of patients with late- vs. early-onset Val30Met transthyretin amyloidosis from the transthyretin amyloidosis outcomes survey (THAOS). Neurol Ther. 2021;10:753–66.

Article  PubMed  PubMed Central  Google Scholar 

Jacobson DR, Alexander AA, Tagoe C, Buxbaum JN. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans. Amyloid. 2015;22:171–4.

Article  CAS  PubMed  Google Scholar 

Arruda-Olson AM, Zeldenrust SR, Dispenzieri A, Gertz MA, Miller FA, Bielinski SJ, et al. Genotype, echocardiography, and survival in familial transthyretin amyloidosis. Amyloid. 2013;20:263–8.

Article  CAS  PubMed  Google Scholar 

Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007–16.

Article  CAS  PubMed  Google Scholar 

Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310:2658–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang C-C, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Eng J Med. 2018;379:11–21.

Article  CAS  Google Scholar 

Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:22–31.

Article  CAS  PubMed  Google Scholar 

Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021;385:493–502.

Article  CAS  PubMed  Google Scholar 

Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, et al. Therapeutic siRNA: state of the art. Signal Transduct Target Ther. 2020;5:101.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Caplen NJ, Mousses S. Short interfering RNA (siRNA)-mediated RNA interference (RNAi) in human cells. Ann N Y Acad Sci. 2003;1002:56–62.

Article  CAS  PubMed  Google Scholar 

Friedrich M, Aigner A. Therapeutic siRNA: state-of-the-art and future perspectives. BioDrus. 2022;36:549–71.

Article  CAS  Google Scholar 

Urits I, Swanson D, Swett MC, Patel A, Berardino K, Amgalan A, et al. A review of patisiran (ONPATTRO®) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis. Neurol Ther. 2020;9:301–15.

Article  PubMed  PubMed Central  Google Scholar 

Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18:421–46.

Article  CAS  PubMed  Google Scholar 

Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369:819–29.

Article  CAS  PubMed  Google Scholar 

Schmidt HH, Wixner J, Planté-Bordeneuve V, Muñoz-Beamud F, Lladó L, Gillmore JD, et al. Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation. Am J Transplant. 2022;22:1646–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

González-Duarte A, Berk JL, Quan D, Mauermann ML, Schmidt HH, Polydefkis M, et al. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. J Neurol. 2020;267:703–12.

Article  PubMed  Google Scholar 

Solomon SD, Adams D, Kristen A, Grogan M, González-Duarte A, Maurer MS, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation. 2019;139:431–43.

Article  CAS  PubMed  Google Scholar 

Fontana M, Martinez-Naharro A, Chacko L, Rowczenio D, Gilbertson JA, Whelan CJ, et al. Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression. JACC Cardiovasc Imaging. 2021;14:189–99.

Article  PubMed  Google Scholar 

APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy). ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT03997383. Accessed 11 Sep 2022.

Topline Results from APOLLO-B Phase 3 Study of Patisiran. alnylampharmaceuticalsinc.gcs-web.com. https://alnylampharmaceuticalsinc.gcs-web.com/static-files/dc61b882-9346-4394-9f5c-dd322727742b. Accessed 11 Sep 2022.

Zimmermann TS, Karsten V, Chan A, Chiesa J, Boyce M, Bettencourt BR, et al. Clinical proof of concept for a novel hepatocyte-targeting GalNAc-siRNA conjugate. Mol Ther. 2017;25:71–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Judge DP, Kristen AV, Grogan M, Maurer MS, Falk RH, Hanna M, et al. Phase 3 multicenter study of revusiran in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther. 2022;34:357–70.

Article  Google Scholar 

Habtemariam BA, Karsten V, Attarwala H, Goel V, Melch M, Clausen VA, et al. Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting n-acetylgalactosamine–small inter